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The co-occurrence of both Alzheimer disease (AD) pathology and vascular brain injury (VBI) is very common,
especially amongst the oldest of old. In neuropathologic studies, the prevalence of AD, VBI, and mixed AD/VBI
lesions ranks ahead of Lewy bodies and hippocampal sclerosis. In the modern era of structural magnetic resonance
imaging (MRI) and amyloid positron emission tomography (PET) imaging, this review examines 1) the prevalence of
mixed AD and VBI pathology, 2) the significance of these pathologies for cognitive impairment (AD and vascular
cognitive impairment (VCI)), and 3) the diagnosis and treatment of mixed AD/VCI. Although epidemiologic studies
report that vascular risk factors for arteriosclerosis increase the risk of incident AD, both autopsy and amyloid PET
studies indicate that AD and VBI contribute additively, but independently, to the risk of dementia. The literature
confirms the malignancy of AD and highlights the adverse effects of microinfarcts on cognitive function. For the
clinical diagnosis of mixed AD/VCI, the presence of AD can be recognized by neuropsychological profile, structural
imaging, cerebrospinal fluid biomarkers, and glucose PET and amyloid PET imaging. The diagnosis of VBI, however,
still hinges predominantly on the structural MRI findings. Severe amnesia and atrophy of the hippocampus are
characteristic of early AD, whereas the cognitive profile for VCI is highly variable and dependent on size and
location of VBI. The cognitive profile of mixed AD/VBI is dominated by AD. With the notable exception of
microinfarcts (which elude in vivo detection), infarcts, hemorrhages, and white matter hyperintensities on structural
MRI currently represent the best markers for the presence VBI. Better markers that reflect the health and reactivity of
intracerebral blood vessels are needed. For prevention and treatment, the type of underlying cerebrovascular
disease (for example, arteriosclerosis or cerebral amyloid angiopathy) should be considered. It is likely that reduction
of vascular risk factors for arteriosclerosis can significantly reduce vascular contributions to mixed dementia.Introduction
Traditionally, Alzheimer disease (AD) and vascular de-
mentia are recognized as the two most prevalent forms of
dementia in late life. A combination of AD and vascular
pathologies (so-called mixed dementia) is usually
registered as a close third, moving up to first or second in
rank in community-based studies of the oldest of old.
Conceptualization and diagnosis of these entities has been
evolving from clinical-pathological phenotypes, which
could not be resolved until autopsy, to new research diag-
nostic criteria that incorporate molecular biomarkers (for
example, amyloid-beta (Aβ) and phosphorylated tau), and
in vivo structural, functional, and perfusion imaging.
Neuropsychological features (for example, pattern and* Correspondence: chui@usc.edu
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remain relevant to diagnosis and clinical care. Innovations
are underway in computerized neuropsychological assess-
ment (for example, computerized assessment with con-
tinuous measures, such as the National Institutes of
Health tool box) and rethinking cognitive impairment in
terms of functional neural networks. In this review, we
consider mainly how recent advances in biomarkers and
imaging have altered our conceptualization and diagnosis
of mixed AD and vascular pathologies.
Medically speaking, the approach to mixed AD and
vascular pathologies should be tied to prevention and
treatment. During the past 30 years, emphasis has
moved from dementia to mild cognitive impairment to
preclinical disease, in the hopes that prevention and
treatment can be instituted earlier in the disease course.
AD is currently conceptualized as a combined amyloido-
pathy and tau-related neurodegeneration. MainstreamMed Central. This is an Open Access article distributed under the terms of the
ativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
al work is properly credited. The Creative Commons Public Domain Dedication waiver
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proteins.
The model for vascular cognitive impairment (VCI)
adopted here posits that vascular risk factors (VRFs) lead
to cerebrovascular disease (CVD), which leads to vascu-
lar brain injury (VBI), which leads to VCI (Figure 1). It
is paramount to maintain focus on the type of CVD (the
cause), as well as on the resulting VBI and VCI. For ex-
ample, the prevention and treatment of cerebral amyloid
angiopathy (CAA), which is intrinsically associated with
AD, is likely to differ fundamentally from the prevention
and treatment of atherosclerosis. It may pay off to pay
some attention to terminology, rather than to lump all
vascular dementias into the category of VCI.
In this review of clinical and imaging features of mixed
AD/VCI, we have chosen nuanced terminology to distin-
guish levels of vascular factors: mixed AD/VRFs, mixed
AD/CVD, mixed AD/VBI, and mixed AD/VCI. We use
the term VCI when clinical criteria are used to define
groups, VBI when study groups are defined by infarcts/
hemorrhages noted by imaging/pathology, and CVD to
refer to specific disorders of blood vessels (for example,
atherosclerosis or amyloid angiopathy). Finally, we use the
term VRFs to refer to traditional risk factors for athero-
sclerosis (for example, hypertension, diabetes mellitus, and
hyperlipidemia) and not for amyloid angiopathy (for ex-
ample, apolipoprotein E (ApoE) ε4 is mentioned distinctly
and not included under the label VRF in this review).Structural MRI (Atrophy, In
















Figure 1 Mixed Alzheimer disease/vascular brain injury. Additive paral
E; CAA, cerebral amyloid angiopathy; CSF, cerebrospinal fluid; CVD, cerebrovas
tomography; VBI, vascular brain injury; VCI, vascular cognitive impairment; VRFThe diagnosis of VCI is reflected in recent clinical cri-
teria [1], which draw heavily on evidence of infarcts,
white matter hyperintensities (WMHs) and microbleeds
(MBs) using structural magnetic resonance imaging
(MRI). Multiple autopsy studies have shown that micro-
infarcts (one type of VBI) are major risk factors for VCI;
however, microinfarcts fall below the resolution of 1.5
and 3 T MRI. This is one of several gaps in in vivo de-
tection that we must close going forward.
For the diagnosis of AD in this review, we adopt
research-level criteria for high likelihood of preclinical,
mild cognitive impairment and dementia due to AD
based on biomarker evidence [2-4]. This requires evi-
dence of 1) amyloid deposition by autopsy, low cerebro-
spinal fluid (CSF) Aβ, or positive amyloid positron
emission tomography (PET) and 2) neurodegeneration
by autopsy, high CSF ptau, and AD pattern of atrophy
on structural imaging. While amyloid and tau bio-
markers are not required in clinical practice for the diag-
nosis of AD, this review is intentionally more selective.
In attempting to define clinical and imaging features
of entities that are defined by clinical and imaging
phenotype, we must be aware of possible circular rea-
soning. For example, in seeking to characterize neuro-
psychological features, we have selected study groups
based on mixed AD/VBI, not mixed AD/VCI (unless the
diagnosis of VCI was reached without knowledge of the
neuropsychological profile).farcts, Bleeds, WMH) 
and PET Imaging) 














lel or interactive pathways? AD, Alzheimer disease; ApoE, apolipoprotein
cular disease; MRI, magnetic resonance imaging; PET, positron emission
, vascular risk factor; WMH, white matter hyperintensity.
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AD/VCI represent an oversimplified dichotomous
framework, necessary for clinical practice. With the
expanding repertoire of neuroimaging modalities, it
makes sense in the long term to adopt a multi-factorial
model that plugs in continuous measures of AD and
VBI as independent variables and looks to continuous
measures of various cognitive domains as the outcome.
Indeed, many of the studies reviewed below used multi-
factorial models where imaging features are correlated
with cognitive performance.
We are now at the infancy of testing whether these
cognitive outcomes are mediated by injury to corre-
sponding cognitive networks (using functional MRI and
diffuse tensor imaging) and how these systems change
over time. We look forward to visualizing how AD path-
ology and VBI impact neural networks and how treat-
ment might protect, sustain, and repair them.
Prevalence of mixed AD/VCI or mixed AD/VBI in
prospective longitudinal autopsy studies
Over four decades ago, the high prevalence of AD and
vascular pathology in older patients (mean age =
76.4 years) was brought to light by Tomlinson, Blessed,
and Roth [5,6]. Previously, AD had been considered a
relatively rare cause of early onset dementia, while ar-
teriosclerosis was widely held to be the most common
cause of late onset dementia. Among 50 cases with de-
mentia living in a mental hospital, widespread plaques
and tangles (that is, AD changes) were the predominant
pathological lesions in 50%, while cerebral softening
(that is, territorial infarcts) due to atherosclerosis
accounted for 12 to 17%, and mixed AD and VBI path-
ologies were found in 8 to 18%. At this juncture, the
pendulum of clinical diagnosis and investigation swung
dramatically from arteriosclerotic dementia to AD.
In 1997, three decades later, the Nun Study heightened
interest in mixed dementia, by showing additive effects
of AD and VBI on risk of dementia [7]. The Nun Study
introduced a generation of prospective, longitudinal,
clinic-to-autopsy cohort studies which have systematic-
ally addressed clinical-pathological correlations in de-
mentia (Tables 1 and 2). We review some of these
studies from the United States, United Kingdom, and
Japan. The prevalence of mixed AD/VBI among cases
with dementia ranges from 14 to 44%.
The Rush Religious Orders Study (ROS) and the Rush
Memory and Aging Project (MAP) constitute parallel,
but independent, longitudinal clinical-pathological stud-
ies. Cases of clinically diagnosed probable AD often re-
vealed a combination of AD plus other pathologies,
especially VBI [8,22]. In the combined ROS and MAP
autopsy samples (n = 804), mixed AD/VBI lesions were
found in 16% of cases between ages 65 and 89 years, andgrew to 28% after age 90 years [23]. Among cases with
dementia, the prevalence of mixed AD/VCI was higher
in the community-based MAP cohort (44%) than in the
religiously defined ROS cohort (28%) [8]. The high
prevalence of mixed AD/VBI and AD/VCI, especially in
the oldest of old, underscores the importance of redu-
cing VRFs as a public health priority.
In the Baltimore Longitudinal Aging Study (BLSA; n =
200), AD pathology alone accounted for 50% of the de-
mentia seen in this cohort; hemispheral infarcts alone
(VBI) or in conjunction with AD pathology (AD/VBI)
accounted for 35%. In subjects with intermediate AD
pathology scores, a single macroscopic hemispheral in-
farct was sufficient to cause dementia [10]. Atheroscler-
osis, brain infarcts, and AD pathology all contributed
independently to risk of dementia [11]. Atherosclerosis
scores were not correlated with AD pathology.
In the population-based Medical Research Council
Cognitive Function and Ageing Study (CFAS; n = 456),
the association between AD pathology (neuritic plaques
and tangles) and cognitive status went down with age,
while the association between atrophy and age contin-
ued to go up [12]. Self-reported VRFs were associated
with infarcts, but not AD pathology [13]. Specifically,
hypertension and heart attack were associated with
microinfarcts in both dementia and non-dementia cases.
In the Cambridge City over-75 s cohort, 22% of 118 de-
mentia cases were classified as mixed AD/VBI [14].
In the population-based Hisayama Study, among 275
cases of incident dementia followed to autopsy, 45%
were classified as AD, 30% as VCI, 5% as mixed AD/VCI
and 4% as dementia with Lewy bodies [15]. The inci-
dences of AD, combined dementia and other types of
dementia rose with increasing age, particularly after the
age of 85 years; this tendency was not observed for VCI
or dementia with Lewy bodies. In an earlier autopsy
study (n = 135), diabetes mellitus and insulin resistance
were associated with neuritic plaques, but not neurofib-
rillary tangles [24].
In the Honolulu Asia Aging Study (HAAS) of older
Japanese American men (n = 443 autopsies), microvascu-
lar lesions were the predominant lesion in 33% of de-
mentia cases, AD the predominant lesion in 18.6% and
mixed lesions (most often AD and VBI) in 14.2% [16].
The frequency of AD pathology and brain atrophy in-
creased steadily after age 72 years (12 to 35% and 25 to
63%, respectively), whereas the frequency of microvascu-
lar lesions remained fairly constant at around 30% across
the older age spectrum. Lewy bodies and hippocampal
sclerosis jumped up in frequency to 15% and 10%, re-
spectively, after age 80 years. The ratio of VBI to AD has
been relatively higher in the HAAS cohort compared
with other cohorts, raising the question of possible eth-
nic differences in gene-environment-brain interactions.










102 87 (76-100) Khachaturian plaque criteria Number of infarcts > or
<1.5 cm
39% (24/61) of dementia
cases were mixed
Number of tangles and number of
lacunes exert independent additive effect
on MMSE and likelihood of dementia
MMSE
CERAD
ROS [8,9] 550 87 Mean number of
neurofibrillary tangles, neuritic
plaques, and diffuse plaques
in five lobes
Number of macroscopic and
microscopic infarcts
28% of dementia cases
were mixed
AD and VBI pathology have additive
effect on odds of dementia
MAP [8,9] 425 87 Mean number of
neurofibrillary tangles, neuritic
plaques, and diffuse plaques
in five lobes
Number of macroscopic and
microscopic infarcts
44% of dementia cases
were mixed
BLSA [10] 179 87.6 ± 7.1 CERAD Macroscopic infarcts Hemispheral infarcts
alone or with AD
account for 35% of
dementia cases
In subjects with intermediate AD pathology
scores, a single macroscopic hemispheral
infarct was sufficient to cause dementia
Blessed Memory
Information
Concentration TestBraak and Braak stage Microscopic infarcts
BLSA [11] 200 Atherosclerosis (0-3) of
coronary, aorta, and
intracranial vessels
45% have remote infarct 68% of cases have atherosclerosis, which
increased the odds of dementia












CERAD scale (0-3) Regional infarcts (>1 cm) Association between AD pathology and
cognitive status goes down with age
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Small vessel disease: lacunes,
microinfarcts, white matter
change
Association between atrophy and age






Vascular risk factors were not associated
with an increased burden of AD
pathology at death in old age
26% of non dementia cases































Table 1 Community-based, autopsy studies are required to estimate the prevalence and incidence of mixed Alzheimer disease/vascular brain injury (Continued)
HAAS [16] N = 443 86 ± 5.2 Mean number of neurofibrillary
tangles and neuritic plaques
over 20 fields in 4 lobes
High correlations noted
between MBIs and lacunar
infarcts (Spearman r = 0.45, P
< 0.0001)
14.2% of dementia cases
were mixed




HAAS [17] N = 436 Number of infarcts > or
<1.0 cm, microinfarcts






MBI and AD exert independent additive
effects on cognition
AD, Alzheimer disease; AGECAT, Automated Geriatric Examination for Computer Assisted Taxonomy; BLSA, Baltimore Longitudinal Aging Study; CASI, Cognitive Abilities Screening Instrument; CC75 + C, Cambridge City
Over-75 s Cohort; CERAD, Consortium to Establish a Registry for Alzheimer Disease; CFAS, Cognitive Function and Ageing Study; CVA, cerebrovascular accident; HAAS, Honolulu Asia Aging Study; MAP, Rush Memory
and Aging Project; MBI, microscopic brain infarct; MMSE, Mini-Mental State Exam; MRC, Medical Research Council; NIA, National Institute on Aging; NINDS-AIREN, National Institute of Neurological Disorders and Stroke-





























Neuropsychology Interaction between VBI






N = 61 78 (at time of
neuropsych)
CERAD CVD-PS Linear composite
measures
AD patient scores were lower than EXEC
by nearly a standard deviation on
average. VBI patients were rather equally
impaired on EXEC,MEM and NVMEM




VBI = 11 GLOB
Mixed = 9 MEM
NSP = 19 EXEC







Positive likelihood ratios: AD = 6.4 >
VCI = 3.7 > mixed = 2.3
AD = 34 At time of
death




AD pathology and hippocampal
sclerosis have relatively greater effect





SIVD study [20] N = 93 84 Lacunes associated with WMH
Normal = 12 AD, atherosclerosis, and VBI contribute independently to cortical gray matter atrophy




SIVD study [21] N = 163 84 Cerebral atherosclerosis was positively associated with microinfarcts (OR, 2.3; 95% CI, 1.2-4.4)
and cystic infarcts (OR, 2.0; 95% CI, 1.0-4.2) but not AD pathology
Normal = 23
AD = 81 Cerebral amyloid angiopathy was inversely associated with lacunar infarcts (OR, 0.6; 95% CI,
0.41-1.1), but positively associated with Braak and Braak stage (OR, 1.5; 95% CI, 1.1-2.1) and








N = 116 84 Pathological measures of AD, atherosclerosis, and VBI contribute independently to MRI cortical
gray matter atrophy and cognitive impairment. Path analyses show that the adverse effects of
atherosclerosis on cognition are largely mediated through subcortical infarcts to brain atrophy,
while the effects of AD on cognition work equally through cortical atrophy as well as through a






AD, Alzheimer disease; ADDTC, Alzheimer’s Disease Diagnostic and Treatment Centers; CERAD, Consortium to Establish a Registry for Alzheimer Disease; CI,
confidence interval; CIND, Cognitive impairment not meeting criteria for dementia; Clin Dx, clinical diagnosis; CN, cognitively normal; CVD-PS, cerebrovascular
disease-parenchymal score; Dem, dementia; EXEC, executive score; GLOB, global cognition score; MEM, memory score; NINDS-ADRDA, National Institute of Neuro-
logical Disorders and Stroke-Association Internationale pour la Recherche et l’Enseignement en Neurosciences; NSP, non-significant pathology; NVMEM, non-verbal
memory; OR, odds ratio; Path Dx, pathological diagnosis; VBI, vascular brain injury; WMH, white matter hyperintensity.
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prevalence, we conclude that mixed AD/VBI ranks in
the top three most prevalent pathologies (with AD and
VCI), well ahead of dementia with Lewy bodies and hip-
pocampal sclerosis. Several studies have noted that the
prevalence of AD pathology and atrophy continue to
grow with advancing age, while the prevalence of in-
farcts remains more constant across the younger, middle
and oldest of old. The prevalence of VBI compared with
AD is higher in studies of Japanese (Hisayama and
HAAS) compared with studies of predominantly Cauca-
sians in the United States and United Kingdom (ROS,
MAP, BLSA, CFAS, Cambridge City over-75 s cohort).However, among infarcts of various sizes, regardless of
ethnicity, microinfarcts show the strongest correlation
with cognitive impairment (HAAS, ROS, CFAS, BLSA).
Consistently, autopsy studies have demonstrated that
VBI and AD exert independent and additive effects on
the risk of dementia.
Weighting the relative effects of VBI, AD, and
other pathological lesions on cognition
Beyond knowing the relative prevalence of pathological
lesions, it is essential to weight their importance for cog-
nitive impairment. The two variables (prevalence and
clinical relevance) are not necessarily correlated. In the
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with normal cognition at enrollment who were followed
longitudinally (mean 7.5 years) had a high prevalence of
neuropathological findings at autopsy (mean age
88 years): 99% evinced plaques or tangles; 36% had at
least one gross infarct; 28% had at least one microinfarct;
and 11% had neocortical Lewy bodies.
The relative weighting of these pathological lesions on
longitudinal cognitive decline was also studied: 22% of
the rate of decline was explained by global AD path-
ology, 6% by amyloid plaques, 34% by tangles, 2% by
macroscopic infarcts, and 8% by neocortical Lewy bod-
ies. When analyzed in conjunction, all pathological indi-
ces explained 41% of the total variation in cognitive
performance. In these two studies combined, the rank
order significance of pathologic lesions for cognitive de-
cline was: tangles > Lewy bodies > amyloid plaques >
macroscopic infarcts.
The prevalence and impact of microinfarcts was exam-
ined in the ROS (n = 425 autopsies) [26]. Microinfarcts
were present in 36.5% of persons with dementia and
25.3% in persons without dementia. The presence of
microinfarcts, especially in multiple cortical locations,
increased the odds of dementia (odds ratio, 1.77; 95%
confidence interval, 1.07 to 2.92) and lowered average
global cognition (estimate, -0.287; standard error (SE),
0.113; P = 0.012). Microinfarcts were associated (in order
of effect size) with lower perceptual speed (estimate,
-0.400; SE, 0.117; P < 0.001), semantic memory (estimate,
-0.391; SE, 0.130; P = 0.003), and episodic memory (esti-
mate, -0.279; SE, 0.138; P = 0.044). These associations
were not modified by the presence of macroscopic in-
farcts or AD pathology, suggesting that the effects of
microinfarcts were independent. Of relevance, 58 of 129
(45%) people with microinfarcts did not have macro-
scopic infarcts, reminding us that we cannot rely on
MRI to exclude VBI.
In the HAAS, 65% of autopsied cases harbored micro-
scopic brain infarcts (MBIs), which contributed signifi-
cantly and independently to brain atrophy and cognitive
impairment, particularly before dementia was clinically
evident [17]. Scalars were developed to represent the se-
verity of five different pathologic lesions (AD, MBI,
hippocampal sclerosis, Lewy bodies, and atrophy). Spear-
man rank correlations (r) between these scalars and the
last Cognitive Abilities Screening Instrument score were
all significant, as follows (in rank order): atrophy,
r = -0.453; AD lesions, r = -0.299; hippocampal sclerosis,
r = -0.200; MBI, r = -0.195; and Lewy bodies, r = -0.158
[27]. The five types of pathology explained 40% of the
variance in the last Cognitive Abilities Screening Instru-
ment score [17].
In the Subcortical Ischemic Vascular Dementia study,
a cohort was recruited from university-affiliated memoryclinics, enriched for people who had lacunes and WMHs
on MRI (Table 2). The correlation between level of cog-
nitive impairment was far stronger with AD pathology
and hippocampal sclerosis than VBI [19]. The profile of
cognitive impairment for neuropathologically defined
mixed AD/subcortical vascular dementia (SVD) resem-
bled that seen in AD cases (memory scores were lower
than executive scores by nearly one standard deviation)
rather than SVD (where all cognitive domains were im-
paired more or less equally) [18]. These finding suggest
that, in general, when SVD is combined with AD, the ef-
fects of AD on severity and profile of cognitive impair-
ment overwhelm those contributed by SVD.
Analyses of these longitudinal, clinical, neuropatho-
logical, and imaging studies have moved our understand-
ing from prevalence to clinical relevance of various
pathological hallmarks. These data confirm the malig-
nancy of AD pathology and highlight the importance of
microinfarcts as one form of VBI. They demonstrate the
usefulness of multivariate, continuous approaches to un-
derstanding brain-behavior relationships. At the same
time, they indicate the limitations of current neuroimag-
ing and neuropathological measures to model and pre-
dict cognitive decline.
Pathological correlates of structural MRI in mixed
AD/VBI
The advent of structural imaging computerized tomog-
raphy (CT) scans in the 1970s and MRI scans in the
1980s) revolutionized our ability to visualize regional at-
rophy and large and small infarcts as well as WMHs and
MBs [28]. A few longitudinal studies have attempted to
validate structural MRI measures (for example, atrophy,
WMHs) in reference to neuropathologic lesions and
cognitive impairment. Pointedly, however, MRI scans at
1.5 and 3 T are not able to visualize microinfarcts, a
form of VBI with demonstrated relevance to cognitive
impairment. Recently, structural MRI at 7 T has revealed
larger microinfarcts (for example, 0.7 mm diameter),
whereas average microinfarcts (0.3 mm diameter) still
fall below the detection threshold [29].
A variety of pathological changes in the brain paren-
chymal and vasculature have been ascribed to WMHs in
late life (reviewed in [30]). Smooth, periventricular rims
and punctuate lesions appear to have little clinical rele-
vance. Irregular and confluent WMHs are correlated
with a host of parenchymal changes (for example, vari-
able loss of myelin and axons, and microglial and in-
flammatory changes) as well as a spectrum of vascular
pathologies (for example, arteriolosclerosis, amyloid
angiopathy, dilated perivascular spaces) [30]. Deep
WMH lesions are thought to result from chronic hypo-
perfusion and hypoxia in terminal vascular beds fed by
long, penetrating arterioles [31] and/or from breakdown
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talloproteinases [32,33]. In the Oregon Brain Aging
Study, arteriolosclerosis (as opposed to atherosclerosis)
was found to be the strongest correlate of WMHs [34].
In patients with AD, loss of fractional anisotropy, and
increased mean and radial diffusivity are seen in white
matter association tracts, especially the corpus callosum
and cingulate and uncinate fasciculi [35,36]. These
changes may be seen in the absence of WMHs, and
most likely reflect secondary (Wallerian) degeneration
from loss of cortical neurons/axons, but to some degree
there is also a component of primary white matter de-
generation [37]. The co-occurrence of WMHs in AD is
commonly associated with the ApoE ε4 genotype, CAA,
or arteriolosclerosis [30,34]. Thus, for the most part,
WMHs in late life can be viewed as a marker for white
matter change related to vasculopathy.
In the Subcortical Ischemic Vascular Dementia study,
volumes of cortical gray matter, WMHs, hippocampus,
and lacunes were obtained from structural MRI and cor-
related with pathology (Table 2). WMHs were straight-
forwardly associated with pathologic measures of
vascular white matter injury; discrete lesions >3 mm and
brighter than CSF correlated well with lacunar infarcts.
On the other hand, neuropathology correlations for hip-
pocampal volume and cortical gray matter were more
complex. Hippocampal sclerosis and AD pathology ex-
plained 33% of the variance in hippocampal volume. A
combination of AD pathology, arteriosclerosis, and sub-
cortical VBI explained 25% of the variance in cortical
gray matter [20].
To improve the clinical diagnosis of mixed AD/VBI,
these findings suggest the requirement for a multi-
variable and multi-modality algorithm. Structural MRI
measures alone have limited sensitivity and specificity.
WMHs, infarcts, and hemorrhages on MRI may be
taken as suitable markers for VBI (minus microinfarcts).
Hippocampal volume is a suitable marker for AD (but
could also mean hippocampal sclerosis). MRI atrophy, at
least as a global measure, cannot be relied upon to dif-
ferentiate a neurodegenerative versus vascular etiology.
Several measures of amyloid and tau pathology (for ex-
ample, amyloid and tau PET or CSF biomarkers) have
been validated and would improve diagnostic specificity
for AD.
Differentiation of mixed AD/VBI in the era of amyloid PET
imaging
Prior to the arrival of amyloid PET imaging [38] and the
validation of CSF biomarkers [39], autopsy was essential
to disclose the neuropathological hallmarks of AD
(namely plaques and tangles). Hence our decision to
begin a review of mixed AD/VCI with neuropathologi-
cally defined AD (Tables 1 and 2). During the past fewyears, however, the detection of early AD changes begin-
ning in preclinical stages has been improved by amyloid
PET ligands (for example, Pittsburgh Imaging Com-
pound B (PiB), florbetapir, flutemetamole, and so on)
[40,41].
A team of investigators at Samsung Medical Center,
Seoul, Korea, separated patients with severe WMHs (evi-
dence of SVD) into two groups based on positive or
negative retention of amyloid on PiB PET scans (Table 3).
Mixed AD/SVD (31% of 45 patients) performed worse
on delayed recall, had fewer lacunar infarcts and had
greater hippocampal atrophy than pure SVD [42]. The
group went on to test the ability of MRI shape analysis
to discriminate mixed AD/SVD from pure SVD [43].
Among 68 patients with SVD defined by severe WMHs,
23 (33.8%) patients were defined as mixed AD/SVD
based on positive PiB binding. With use of hippocampal
shape analysis alone, mixed SVD could be distinguished
from pure SVD with 95.7% sensitivity and 68.9% specifi-
city. With use of amygdalar shape, the discrimination ac-
curacy was 87.0% sensitivity and 68.9% specificity. The
two groups could also be distinguished based on the
shape of the hippocampus and amygdala.
In the Aging Brain Study [44,45], a longitudinal cohort
enriched for vascular disease, no associations were found
between measures of VBI on MRI and amyloid retention
on PiB PET (Table 3). Participants with infarcts showed
lower executive functioning (P = 0.001). Subcortical in-
farcts were inversely associated with declines in execu-
tive and memory function, whereas cortical infarcts were
mainly associated with decline in executive function.
Global PiB retention was associated with diminished
non-verbal memory. Within this spectrum of normal
aging to mild dementia, VBI and Aβ aggregation ap-
peared to be independent processes with VBI having a
greater impact on cognition than PiB retention. These
studies illustrate how amyloid PET imaging will greatly
improve our ability to recognize mixed AD/VCI cases of
dementia.
Differentiation of mixed AD/VBI with CSF biomarkers
CSF biomarkers for Aβ42 and tau also provide molecu-
lar evidence for AD, but the findings are more difficult
to interpret. In the Amsterdam Dementia Cohort, the
presence of both MBs and WMHs was associated with
lower CSF levels of Aβ42, while lacunar infarcts were as-
sociated with higher Aβ42 and lower tau (Table 4) [49].
The investigators concluded that the data supported a
direct relationship between SVD and AD pathology.
However, if type of SVD is considered (that is, athero-
sclerosis versus CAA), the direct relationship between
MBs and WMHs and AD biomarkers might reflect
underlying CAA and AD, driven in common by ApoE ε4
genotype.
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infarcts and had greater hippocampal atrophy than pure SVD.
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Hippocampal shape analysis: 95.7% sensitivity; 68.9% specificity
PiB- PiB+ Amygdalar shape analysis: 87.0% sensitivity; 68.9%
Aging Brain
Study [44]
N = 54 79 PiB+ VBI: WMHs
and infarcts
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VBI is associated with impairment in EXEC
N = 33
PiB-
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Aging Brain
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N = 61 79 VBI: Infarcts Infarction, particularly in cortical and subcortical gray matter,
was associated with lower cognitive performance in all domains










N = 43 78.9 (6.7) FCRP accounted for 16% of the variance in PiB index (P < 0.008) and the positive association remained
significant controlling for age and sex, and apolipoprotein E genotype
Aging Brain
Study [47]
N = 74 79 Higher LDL-C and lower HDL-C levels were both associated with a higher PiB index,






N = 67 79 A relationship between Aβ and memory was mediated by cortical thickness.
35 NCI The relationship between Aβ and cortical thickness was eliminated after controlling for FCRP, except in
PiB+ subjects (n = 22), where Aβ remained associated with thinner cortex in precuneus and occipital lobe
31 MCI
1 CDR1 Vascular risk and Aβ both contribute to cortical thickness
Aβ, amyloid-beta; AD, Alzheimer disease; CDR, Clinical Dementia Rating; EXEC, executive score; FCRP, Framingham Coronary Risk Profile; HDL-C, high density lipo-
protein cholesterol; LDL-C, low density lipoprotein-cholesterol; MCI, mild cognitive impairment; NCI, no cognitive impairment; PET, positron emission tomography;
PiB, Pittsburgh Imaging Compound B; SVD, subcortical vascular dementia; VBI, vascular brain injury; WMH, white matter hyperintensity.
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were not associated with AD biomarkers (that is, CSF
amyloid, [18 F]fluorodeoxyglucose (FDG) PET uptake or
MRI hippocampal atrophy). In normal controls, progres-
sive increases in WMH over time were associated with
greater decline in executive function and lower FDG PET
uptake (Table 4) [50]. One should keep in mind that the
Alzheimer Disease Neuroimaging Initiative is focused on
AD not CVD. The Framingham Coronary Risk Profile
scores for the cohort were relatively low, approximately
18% across normal cognition, mild cognitive impairment
and AD groups. Nonetheless, no interactions were noted
between VRFs and AD biomarkers.Other possible pathophysiological interactions
between VRFs, CVD, and AD pathology
Converging evidence from epidemiologic [51-53], neuro-
pathologic, amyloid PET, and CSF biomarker studies
show that VBI and AD exert additive adverse effects on
cognitive health (Figure 1). Do VRFs and CVD merely
increase the co-occurrence of two separate processes
(that is, AD and silent/symptomatic VBI), which shifts
the syndromal diagnosis of dementia and AD earlier
(reviewed in [9,54])? Or do VRFs and CVD potentiate
AD-specific pathophysiological pathways, such as amy-
loidopathy and tauopathy? Several mechanisms have
been postulated by which Aβ may be cleared in the
Table 4 Studies of mixed Alzheimer disease/vascular brain injury with Alzheimer disease defined by cerebrospinal fluid
Aβ and phosphorylated tau
Study N AD = VCI/VBI VBI and AD correlations
ADNI [50] N = 819 NINDS-
ADRDA
VRFs VRFs were not associated with AD biomarkers
229 NCI WMH Increased time-varying WMHs were associated with faster decline in










The presence of both MBs and WMHs was associated with lower CSF levels of
Aβ42, indicating a direct relationship between SVD and AD pathology
(note: could SVD be CAA?)337 NCI
547 AD
30 VCI The presence of lacunes was associated with higher Aβ42 in vascular dementia
(standardized beta = 0.17, P = 0.07) and lower tau in AD (standardized beta = -0.07,
P = 0.05) but there were no effects for Aβ42 or phosphorylated tau181 in AD
(note: could SVD with lacunes be arteriolosclerosis?)
Aβ, amyloid-beta; AD, Alzheimer disease; ADNI, Alzheimer’s Disease Neuroimaging Initiative; CAA, cerebral amyloid angiopathy; CI, cognitively impaired; CSF,
cerebrospinal fluid; FDG, [18 F]fluorodeoxyglucose; MB, microbleed; NCI, no cognitive impairment; NINDS-ADRDA, National Institute of Neurological Disorders and
Stroke-Association Internationale pour la Recherche et l’Enseignement en Neurosciences; NINDS-AIREN, National Institute of Neurological Disorders and
Stroke-Association Internationale pour la Recherche et l’Enseignement en Neurosciences; SVD, subcortical vascular dementia; VBI, vascular brain injury; VCI,
vascular cognitive impairment; VRF, vascular risk factor; WMH, white matter hyperintensity.
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insulin degrading enzyme) by microglia and astrocytes;
2) active transport from brain to blood through an endo-
thelial lipoprotein receptor-related protein-mediated
process [55-57]; and 3) passive transport through a peri-
vascular ‘lymphatic-like’ drainage system of the brain
[58,59]. Recently, associations between the accumulation
of Aβ on PiB PET scans with serum cholesterol and aor-
tic arterial stiffness have been described [46,47,60]. How-
ever, direct associations between Aβ clearance and levels
of brain cholesterol or cerebral arteriolar/venous stiff-
ness in human beings have yet to be shown. Thus, inter-
actions at the pathophysiological level between VRFs/
CVD and AD pathology, while plausible, are still
unresolved.
Type of cerebrovascular disease matters for
prevention and treatment
VCI and VBI refer to phenotypes rather than treatable
etiologies. It should be apparent that clinical diagnosis
must go further to identify the underlying type of CVD.
While there are many possible types of CVD, the three
major types are atherosclerosis, arteriolosclerosis, and
CAA. Risk factors for atherosclerosis and arteriolosclero-
sis overlap considerably and include hypertension, dia-
betes mellitus, and hyperlipidemia, which are easily
measured and effectively treated with medications and
lifestyle modifications.
The location of some, but not all, structural imaging
features may help to distinguish underlying arteriolo-
sclerosis from CAA. WMHs are associated with both
hypertensive arteriosclerosis and severe CAA, with evi-
dence of a more posterior location favoring CAA
[61,62]. Lacunar infarcts are more likely to be associatedwith arteriolosclerosis than with CAA [21]. The regional
distribution of MBs may help to differentiate SVD and
CAA; the occurrence of MBs in deep gray nuclei sug-
gests SVD, while MBs in lobar or cortical regions sug-
gest CAA [63,64]. Though promising, the sensitivity and
specificity of categorizing strictly lobar as CAA, strictly
deep as hypertensive vasculopathy, or both lobar and
deep as coexisting CAA and hypertensive vasculopathy
has not yet been studied [64].
Evidence-based treatment recommendations for VCI
have been recently reviewed [1]. Also, based on compre-
hensive reviews of the literature, and assuming a causal re-
lationship and intervention at an appropriate age to
reduce the prevalence of each of seven risk factors by 10%
per decade, it has been estimated that the prevalence of
AD/dementia could be reduced by 8.3% worldwide by
2050 [53]. This would translate to 1.1 to 3 million AD/de-
mentia cases worldwide and 184,000 to 492,000 cases in
the USA [65]. These risk factors include five vascular risk
factors (that is, midlife hypertension, diabetes mellitus,
mid-life hyperlipidemia, smoking, sedentary life style), as
well as depression and low educational attainment. Argu-
ably the epidemiological diagnosis of AD may well include
cases with subclinical VBI or mixed AD/VBI. Regardless
of etiological label, assuming internal consistency in the
definitions of risk factors and the diagnosis of dementia
subtype, the epidemiological data present a valid and
worthy public health objective, namely a 10% reduction in
VRFs for 10 years for an 8% reduction in dementia.
The major risk factor for CAA is the ApoE ε4 allele,
which can be determined readily by genotyping, though
is not yet recommended by best practice guidelines.
Strategies to reduce risks related to the ApoE ε4 geno-
type have been explored in cultured neurons [66] and in
Note: This article is part of a series on Cerebral multi-morbidity of the
aging brain edited by Johannes Attems and Julie Schneider. Other
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plaques in animals, but no clinical trials have been con-
ducted in humans.articles in the series can be found at http://alzres.com/series/
cerebral_multimorbidity.Conclusion
The co-occurrence of AD and VBI in elderly persons is
very common. There is now a large body of evidence
showing that AD and VBI lead in an additive and inde-
pendent fashion to cognitive dysfunction. In AD, there is
a characteristic pattern of tau-related, neurofibrillary
neurodegeneration spreading from the medial temporal
lobe to other multi-modal association areas and a corre-
sponding pattern of memory loss spreading to other
cognitive domains. By contrast, there is tremendous
variation in the neuropsychological profile associated
with VBI. In the SVD subtype of VCI, executive dysfunc-
tion often equals or may exceed memory impairment,
but depending on location all varieties of cognitive im-
pairment may ensue.
WMHs, small and large infarcts and hemorrhages are
visible on structural MRI and CT imaging and currently
serve as the most reliable marker for VBI. However,
microinfarcts, which have been most strongly related to
cognitive impairment in neuropathology studies, con-
tinue to elude clinical detection. The validation of amyl-
oid PET imaging adds considerable specificity for the
diagnosis of AD, beyond the long recognized atrophy of
the hippocampus. The addition of tau PET imaging is
expected shortly. Global measures of atrophy on MRI
are important markers of overall brain injury, but cannot
be used reliably to determine etiology.
Longitudinal studies with repeat neuropsychological
testing support multivariate approaches to model the ef-
fects of various types of pathology on dementia risk and
cognitive decline. Once comparable measures of AD and
VBI pathology are available from in vivo neuroimaging
studies, we can anticipate that one day dichotomous
classifications will be replaced by more sophisticated
modeling. Still, the best models available today predict
less than half of the variance in cognitive performance.
For prevention and treatment, it is important to bear
in mind the type of CVD underlying VBI and VCI, as
well as to consider that subclinical CVD and VBI may
contribute additively to cognitive impairment in patients
with AD. Epidemiological data suggest that attention to
‘life’s simple seven’, referring to seven health factors and
lifestyle behaviors identified by the American Heart As-
sociation that include being physically active, eating
foods low in cholesterol and saturated fats, monitoring
high blood pressure and blood sugar, maintaining a
healthy weight, controlling cholesterol, and avoiding to-
bacco smoking, can significantly reduce the risk of
dementia.Abbreviations
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